Using a decline in serum hCG between days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate:a retrospective cohort study by Skubisz, Monika et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using a decline in serum hCG between days 0-4 to predict
ectopic pregnancy treatment success after single-dose
methotrexate
Citation for published version:
Skubisz, M, Dutton, P, Duncan, WC, Horne, AW & Tong, S 2013, 'Using a decline in serum hCG between
days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective
cohort study' BMC pregnancy and childbirth, vol 13, 30. DOI: 10.1186/1471-2393-13-30
Digital Object Identifier (DOI):
10.1186/1471-2393-13-30
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BMC pregnancy and childbirth
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and
reproduction in any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
RESEARCH ARTICLE Open Access
Using a decline in serum hCG between days 0–4
to predict ectopic pregnancy treatment success
after single-dose methotrexate: a retrospective
cohort study
Monika Skubisz1,2*†, Philip Dutton3†, William Colin Duncan3, Andrew W Horne3 and Stephen Tong1†
Abstract
Background: The current measure of treatment efficacy of single-dose methotrexate for ectopic pregnancy, is a fall
in serum hCG of ≥15% between days 4–7 of treatment, which has a positive predictive value of 93% for treatment
success. Two small studies have proposed a fall in serum hCG between days 0–4 after treatment confers similar,
earlier prognostic information, with positive predictive values of 100% and 88% for treatment success. We sought to
validate this in a large, independent cohort because of the potentially significant clinical implications.
Methods: We conducted a retrospective study of women (n=206) treated with single-dose methotrexate for
ectopic pregnancy (pre-treatment serum hCG levels ≤3000 IU/L) at Scottish hospitals between 2006–2011. Women
were divided into two cohorts based on whether their serum hCG levels rose or fell between days 0–4 after
methotrexate. Treatment outcomes of women in each cohort were compared, and the test performance
characteristics calculated. This methodology was repeated for the current measure (≥15% fall in serum hCG
between days 4–7 of treatment) and an alternate early measure (>20% fall in serum hCG between days 0–4 of
treatment), and all three measures were compared for their ability to predict medical treatment success.
Results: In our cohort, the positive predictive value of the current clinical measure was 89% (95% CI 84-94%)
(121/136). A falling serum hCG between days 0–4 predicted treatment success in 85% (95% CI 79-92%) of cases
(94/110) and a >20% fall in serum hCG between days 0–4 predicted treatment success in 94% (95% CI 88-100%) of
cases (59/63). There was no significant difference in the ability of these tests to predict medical treatment success.
Conclusions: We have verified that a decline in serum hCG between days 0–4 after methotrexate treatment for
ectopic pregnancies, with pre-treatment serum hCG levels ≤3000 IU/L, provides an early indication of likelihood of
treatment success, and performs just as well as the existing measure, which only provides prognostic information
on day 7.
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Background
Ectopic pregnancies occur in 1-2% of pregnancies [1].
Although potentially life threatening, the ability to non-
invasively detect ectopic pregnancies before they rupture
with ultrasound affords some women the option of med-
ical management. Stovall et al. [2] first demonstrated the
safety and efficacy of outpatient methotrexate to treat
women with ectopic pregnancies in 1989, and today, ap-
proximately 25-30% of women presenting with this con-
dition are eligible for such treatment [3,4].
Quantification of serum hCG provides a sensitive bio-
marker of viable trophoblastic tissue and is used in the
medical treatment of ectopic pregnancy to monitor
treatment response. In the single-dose methotrexate
protocol developed by Stovall et al. [2,5], treatment effi-
cacy is determined by a ≥15% fall in serum hCG between
days 4 and 7 of treatment; if there has been an insuffi-
cient fall in serum hCG at this time, further doses of
methotrexate and/or surgery are indicated. This measure
has been validated by Kirk et al. [6] and shown to have a
positive predictive value of 93% for treatment success.
By definition, however, the first indication of treatment
efficacy can be ascertained no earlier than day 7.
In 2010, Nguyen et al. [7] reported that a fall in serum
hCG between days 0–4 after methotrexate injection pre-
dicted treatment success with no further intervention in,
remarkably, 100% of cases (n=30). Investigating a cohort
of 45 women in a follow-up study, we reported that a fall
in serum hCG between days 0–4 predicted treatment
success after single-dose methotrexate in 88% of cases
[8]. Furthermore, an earlier study by Agostini et al. [9]
of 129 cases of ectopic pregnancy reported that a ≥20%
fall in serum hCG between days 1–4 after medical treat-
ment with a single dose methotrexate had a positive pre-
dictive value of 97% for treatment success.
The fact that serum hCG trends may be able to accur-
ately predict treatment outcomes for many women as
early as day 4 has potentially important clinical implica-
tions. Firstly, it significantly reduces the duration of anx-
ious uncertainty patients (and clinical staff ) must endure
before obtaining an indication of whether or not the
treatment is working. Secondly, it raises the possibility
of changing protocols in medical management of ectopic
pregnancy and intervening with a second dose of metho-
trexate earlier in cases where serum hCG levels have not
fallen between days 0–4, to potentially improve overall
methotrexate treatment success rates and/or decrease
the length of time required to achieve a successful reso-
lution of the ectopic pregnancy.
However, before proposing a fall in day 0–4 serum
hCG should be used clinically as an early prognostic in-
dicator for medical treatment success in management of
ectopic pregnancies, we felt it important to perform a
further validation using a large, independent cohort,
especially given that the two previous studies featured
small numbers of women (n=30 and 45, respectively)
[7,8]. Therefore, we examined the ability of a fall in
serum hCG between days 0–4 to predict treatment suc-
cess after single-dose methotrexate treatment for ectopic
pregnancy in a cohort of 206 Scottish women.
Methods
Objective
A retrospective cohort study was performed to assess
the prognostic value of a fall in serum hCG between
days 0–4 after medical treatment of ectopic pregnancy
with single-dose methotrexate.
Participants
The South East Scotland Research Ethics Service deemed
that this study did not require formal NHS ethical review,
as the project was audit based and used only data obtained
as part of routine care.
Data was collected from electronic and linked records
for women treated with single-dose methotrexate for ec-
topic pregnancy in early pregnancy units in Scotland be-
tween 2006 and 2011. Data for the year 2006 was
available for women treated at all 11 Scottish early preg-
nancy units (n=210) and for treatment episodes between
2007 and 2011, records were collected from the Royal
Infirmary of Edinburgh’s Pregnancy Support Centre
(n=187). Data collected included baseline demographics,
treatment dates and outcomes and serial serum hCG
measurements.
Available patient data was classified and only included
if it fulfilled the ectopic pregnancy diagnostic criteria
published in the consensus statement of early pregnancy
outcomes [10].
Scottish protocols stipulate that to be eligible for out-
patient medical management of ectopic pregnancy, a
woman must be haemodynamically stable and reliable
for follow up, the pre-treatment serum hCG should be
<3000IU/L and the diagnostic ultrasound should show a
gestational sac size no greater than 4cm in largest diam-
eter, with little or no pelvic free fluid. Eligible women
were treated as outpatients with a single dose of intra-
muscular methotrexate at 50 mg/m2.
Furthermore, to be included in our analysis, partici-
pants needed to have a recorded serum hCG on day 0 or
1, day 4 and day 7 of treatment, as well as a documented
treatment outcome i.e. successful medical management
with or without further doses of methotrexate, or failed
medical management requiring surgery.
We have previously noted confusion both clinically and
in the literature relating to the day of treatment, with both
day 0 and day 1 being used to denote the day of metho-
trexate injection [8]. The original protocol proposed by
Stovall et al. [5] considers the day of treatment to be day
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1, however, the study by Nguyen et al. [7] designated day
0 as the day of treatment. We have thus included women
with either a day 0 or day 1 serum hCG recorded.
Description of analysis
In order to achieve a dichotomous outcome (i.e. suc-
cess/failure), we have for the purposes of this analysis
defined treatment success as a complete resolution of
serum hCG to <15IU/L after a single dose of methotrex-
ate with no further intervention, medical or surgical.
Thus, cases requiring repeat doses of methotrexate or
surgical management were classified under treatment
failure in this study.
Participants were divided into two cohorts based on
whether their serum hCG rose or fell between days 0–4
after single-dose methotrexate for ectopic pregnancy
(day 0/1 serum hCG - day 4 serum hCG). The positive
predictive value, negative predictive value, sensitivity and
specificity were calculated.
We used this method to assess the prognostic value of
other measures of treatment efficacy: 1) a ≥15% fall in
serum hCG between days 4–7 of medical treatment
((day 4 – day 7 serum hCG/ day 4 serum hCG) x 100)
and 2) a ≥20% fall in serum hCG between days 0–4 of
treatment ((day0/1 - day 4 serum hCG/day 0/1 serum
hCG) x 100), as proposed by Agostini et al. [9].
Statistical analysis
The ability of each measure to predict single-dose
methotrexate treatment success in ectopic pregnancy
was compared using Fisher’s exact test. Baseline clinical
demographics were compared using a Student’s t test for
continuous variables and a Fisher’s exact test for cat-
egorical variables. For each measure, we calculated sensi-
tivities, specificities, positive and negative predictive
values. Statistical analysis was performed using PRISM
(GraphPad, La Jolla, CA, USA).
Results
Participants
Records were available for a total of 397 women treated
with single-dose methotrexate for ectopic pregnancy be-
tween 2006–2011, using local protocols based on the
RCOG guideline [11]. Of these: 2 were lost to follow up
or had no recorded serum hCG levels, 38 had no
recorded day 0 or 1 serum hCG, 104 women had no
recorded day 4 serum hCG and 32 had no recorded day
7 serum hCG. A further 13 women were excluded for
having a pre-treatment serum hCG of >3000IU/L and 2
had no documented treatment outcome. This left 206
women suitable for analysis.
The baseline characteristics of the cohort include a
mean day 0 (or day 1) hCG level of 778.2 IU/L (SEM ±
49.25), a mean age of 30.8 (SEM ± 0.4) years, a previous
ectopic pregnancy rate of 14% (28/206), previous
recorded chlamydial infection in 18% (36/206) and 24%
of the cohort were current or past smokers 49/206). All
participants demonstrated a gestational sac size of <4cm
and up to moderate amounts of pelvic free fluid on
ultrasound.
Treatment outcomes
The treatment success rate achieved with a single dose
of methotrexate i.e. without need for a subsequent dose
of methotrexate and/or surgery in the overall cohort was
71% (147/206). 40 women (19%) required further doses,
so that the overall medical treatment success rate (allow-
ing for additional doses of methotrexate) was 90% (186/
206). 20 women (10%) required surgical management.
Falling hCG between days 0–4 to predict medical
treatment success
110/206 women demonstrated a falling serum hCG be-
tween days 0–4 of treatment (mean hCG fall −161 IU/L
(SEM ± 21.5)); of these, 94/110 women experienced treat-
ment success with a single dose of methotrexate (no re-
peat doses), giving this measure a positive predictive value
of 85% (95% CI 79-92%). The sensitivity and specificity for
a falling hCG between days 0–4 to predict single-dose
methotrexate treatment success were 64% and 73%, re-
spectively, and the negative predictive value 46%.
Of the remaining 96/206 women who had a rising
serum hCG between days 0–4 (mean hCG rise 317 IU/L
(SEM ± 32.2)), 53/96 (55%) experienced medical treat-
ment success (i.e. negative predictive value of 45%).
We examined the pre-treatment serum hCG trends of
participants with a falling serum hCG between days 0–4,
to show that the early falling hCG levels were an effect of
treatment and not just a pre-existing trend. The pre-
treatment serum hCG trend was available for 98/110 of
women with a falling serum hCG betweens days 0–4. Ob-
servation of pre-treatment hCG levels ranged from 1–32
days prior to methotrexate administration. A rising hCG
trend was noted in 61/98 (62%) women in this cohort
prior to treatment, and of these, 52/61 (85%) were suc-
cessfully treated with one dose of methotrexate; 9/61
(15%) required either additional doses of methotrexate or
surgical management. A falling pre-treatment hCG trend
was noted in 37/98 women in this cohort, with 31/37
(84%) of these successfully treated and 6/37 (16%) requir-
ing additional doses of methotrexate and/or surgery.
≥15% Fall in hCG between days 4–7 to predict
medical treatment success
Using the current test of medical treatment efficacy in
ectopic pregnancy, 136/206 women demonstrated a
≥15% fall in serum hCG between days 4–7. Of these,
121/136 women experienced treatment success resulting
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in a positive predictive value of 89% (95% CI 84-94%). Of
the 70/206 women whose serum hCG did not fall by ≥15%
between days 4–7, 25/70 (36%) experienced treatment suc-
cess (negative predictive value of 64%). The sensitivity of
this measure to predict treatment success was 82% and
specificity 75%.
≥20% Fall in hCG between days 0–4 to predict
medical treatment success
63/206 women had a ≥20% fall in their serum hCG con-
centrations between days 0–4. Of these, 59/63 experi-
enced treatment success providing a positive predictive
value of 94% (95% CI 88-100%). Of the 143/206 women
where serum hCG did not fall ≥20% between days 0–4,
87/143 (61%) experienced treatment success (i.e. nega-
tive predictive value 39%). The sensitivity of this meas-
ure to accurately predict medical treatment success was
40% and the specificity 93%. The test characteristics of
all 3 measures are summarised in Table 1.
Comparison of the predictive value of the 3 measures
There was no significant difference between the ability
of any of the tests to accurately predict medical treat-
ment success with a single dose of methotrexate when
comparing them individually using Fisher’s exact test
(p=≥0.13).
Discussion
This study shows that a fall in serum hCG between days
0–4 of treatment represents an 85% likelihood of treat-
ment success with no further intervention, medical or
surgical, for single-dose methotrexate treatment of ec-
topic pregnancy. We analysed the early serum hCG
trends of 206 women treated with single-dose metho-
trexate for their ectopic pregnancies in a range of treat-
ment centres, and these are numbers far greater than
previously reported (n=30, n=45 and n=129) [7-9].
A large number of women were excluded from our
analysis due to inaccurate timing of (or missed) serum
hCG level measurements, in contrast to the require-
ments of the single-dose methotrexate treatment proto-
col. Specifically, the analyses performed in this study
required serum hCG levels to be available for days 0 or
1, day 4 and day 7 after methotrexate treatment. While
this raises the possibility of a selection bias, it is not im-
mediately clear how this may have affected our results.
Certainly attendance at such numerous and specific time
points for serum sampling requires significant patient
(and physician) compliance, but non-compliance is un-
likely to have any bearing on treatment outcome, which
was the primary outcome assessed in this study. Indeed,
the results obtained are consistent with those of previ-
ous studies in other populations [7-9]. This study there-
fore, strengthens the validity of the prognostic value of a
falling serum hCG between days 0–4 after single-dose
methotrexate treatment for ectopic pregnancy.
Treatment success for the purposes of this study was
defined more strictly than in the current protocol and
clinical practice, in that it did not allow for any add-
itional doses of methotrexate. This was for the purposes
of rigorously testing the prognostic value of a falling
serum hCG between days 0–4 for an actual single (ra-
ther than a variable) dose methotrexate treatment
course. Allowing for additional doses of methotrexate is
likely to only improve the positive predictive value of
this measure.
The application of a quantified ≥20% fall in serum hCG be-
tween days 0–4 of medical treatment improves the positive
predictive value from 85% to 94%. This is likely explained by
the fact that the greater the fall in serum hCG between days
0–4 of treatment, the more likely the patient is to experience
treatment success. There is a clear trade-off, however, be-
tween increasing accuracy of prediction with such a cut-off
(specificity) and clinical applicability of this measure to a
Table 1 Summary test characteristics of each of the 3
measures analysed
TEST 1: Falling hCG between days 0-4
Treatment
Success
Treatment
Failure
Total
Falling
hCG
94 16 110 PPV: 85% (95% CI
79-92%)
Rising
hCG
52 44 96 NPV: 46%
Total 146 60 206
Sensitivity: Specificity:
64% 73%
TEST 2: ≥15% Fall in hCG between days 4-7
Treatment
Success
Treatment
Failure
Total
Falling
hCG
121 15 136 PPV: 89% (95% CI
84-94%)
Rising
hCG
25 45 70 NPV: 64%
Total 146 60 206
Sensitivity: Specificity:
83% 75%
TEST 3: >20% Fall in hCG between days 0-4
Treatment
Success
Treatment
Failure
Total
Falling
hCG
59 4 63 PPV: 94% (95% CI
88-100%)
Rising
hCG
87 56 143 NPV: 39%
Total 146 60 206
Sensitivity: Specificity:
40% 93%
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greater number of women (sensitivity). The sensitivity of a
falling serum hCG between days 0–4 fell substantially from
64% to 40% when a ≥20% cut-off was applied, so that the test
could only provide meaningful prognostic information to
29% (59/206) of women. In contrast, prognostic information
was available for 53% (110/206) of women if any fall in
serum hCG between days 0–4 was used as the cut-off for a
measure of treatment efficacy, with no difference in prognos-
tic accuracy.
It is possible that women with a falling serum hCG be-
tween days 0–4 after single-dose methotrexate for ectopic
pregnancies may have had already failing pregnancies and
did not require treatment. This was not the case, however,
as inspection of the pre-treatment serum hCG trends for
women with early falling serum hCG levels after metho-
trexate indicated that the majority (62%) in fact had rising
serum hCG levels prior to treatment. Interestingly, regard-
less of a rising or falling pre-treatment hCG trend, a falling
serum hCG level between days 0–4 predicted single-dose
methotrexate treatment success with equal measure in this
sub-cohort of women (85% and 84%, respectively).
This study examined ectopic pregnancies with pre-
treatment serum hCG levels of ≤3000 IU/L, and the
results may not apply to medically treated ectopic preg-
nancies with pre-treatment serum hCG levels >3000 IU/L.
Furthermore, given that a fall in serum hCG between days
0–4 is not 100% predictive of treatment success, it is
still prudent to continue monitoring hCG levels until
normalisation.
Conclusions
We have found that a fall in serum hCG between days
0–4 after single-dose methotrexate treatment of ectopic
pregnancy (where the pre-treatment serum hCG is ≤3000
IU/L), predicts treatment success in 85% of cases, with no
further intervention required (medical or surgical).
With this measure, prognostic information is obtained
three days earlier than from the current, standard clin-
ical measure, and with comparable accuracy. This raises
the possibility of altering existing methotrexate proto-
cols, with the aim of increasing medical treatment suc-
cess rates, by intervening with an earlier repeat dose
where early serum hCG levels are still rising; this would,
however, require further investigation.
We believe that clinical staff caring for women with
ectopic pregnancies, treated with single-dose methotrex-
ate, can confidently use a falling serum hCG between
days 0–4 of treatment to provide earlier prognostic in-
formation and reassurance to patients with this poten-
tially life-threatening condition.
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